OVID · Ovid Therapeutics Inc.
$2.83
+0.03 (+1.07%)
At close · Aug 14
Market Cap
$552.69M
Shares
195.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.83
Open$2.80
Day$2.75–2.87
52W close$0.84–2.96
Avg vol 30d1.6M
Short int21.5M · 11.0% float · 14.0d
Short vol66%
Last earningsMar 18, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+36%
above
Price vs 50-day avg
+14%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
94%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+95%
trailing
YTD return
+74%
this year
Relative strength
+81%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.99% of float · ▼ -2.6% MoM · 14.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
130 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+1181%
Y/Y
EPS growth
+4%
Y/Y
Free cash flow
$-38.3M
Balance sheet
$13.2M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+36%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
94%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.99% of float · ▼ -2.6% MoM · 14.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
130 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $3 · 94%
Range high $3
vs 200-day avg +36%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OVID
this stock
Ovid Therapeutics Inc.
|
$552.69M | +73.6% | +1181.3% | — | 11.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OVID | +7.6% | +16.0% | +95.2% | +27.5% | +73.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +7.2% | +11.5% | +81.4% | +23.6% | +59.8% |
Key facts
CIK
1636651
CUSIP
690469101
13F (30d)
134 filings
128 filers
Visit website
Investor relations